30 September 2020 - Phase 3 GO-VIVA clinical trial adds to the growing body of evidence for Simponi Aria.

Janssen announced today that the U.S. FDA has approved Simponi Aria (golimumab) for patients 2 years of age and older for the treatment of active polyarticular juvenile idiopathic arthritis and has extended the psoriatic arthritis indication for this same patient population.

The approval was based on results from the GO-VIVA Phase 3 clinical trial, an open-label study in children with juvenile idiopathic arthritis with active polyarthritis ages 2 to 17 years who had active arthritis in five or more joints, despite receiving treatment with methotrexate for at least two months.

Read Janssen press release